| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology (Drs. Deisenhammer, Reindl, Gasse, Dilitz, and Berger), University of Innsbruck, Austria; and Chiron Diagnostics (Dr. Harvey), Alameda, CA.
Address correspondence and reprint requests to Dr. Florian Deisenhammer, Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.
BACKGROUND: Neutralizing antibodies (NAB) to interferon beta (IFNß) occur in about one-third of MS patients treated with IFNß-1b and there is an association with a loss of clinical and MRI efficacy. However, there are no data regarding the bioavailability of IFNß-1b in patients with and without NAB.
METHODS: The authors measured MxA in whole blood by ELISA, and serum-binding antibodies (SBA) by Western blot and ELISA in 134 samples of MS patients on IFNß-1b and 54 control subjects, and correlated the MxA levels and SBA titers with the NAB titer.
RESULTS: In the IFNß group 84 samples were NAB negative, 21 were NAB positive (i.e., titer of 
20), and 29 had detectable NAB (i.e., titer between 10 and 20). The median MxA concentration in NAB-negative patients was 4.09 ng/105 peripheral blood leukocytes (PBL), 2.37 ng/105 PBL in samples with detectable NAB, 0.36 ng/105 PBL in NAB-positive samples, and 0.27 ng/105 PBL in control subjects. There was no significant difference between NAB-positive samples and control subjects, otherwise the groups differed significantly from each other. SBA occurred in 49% of NAB-negative samples, in 79% of samples with detectable NAB, and in all NAB-positive samples. With regard to the SBA titer, all groups differed significantly from each other. In none of the control samples were SBA detected.
CONCLUSION: The conversion of SBA into NAB depends to some degree on the SBA titer, but other mechanisms may be involved. Once NAB have developed, the bioavailability of IFNß as measured by MxA is completely inhibited.
This article has been cited by other articles:
|
|
 |
|
  M Ravnborg, K Bendtzen, O Christensen, P. Jensen, D Hesse, M. Tovey, and P. Sorensen Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis Multiple Sclerosis, March 1, 2009; 15(3): 323 - 328. [Abstract] [PDF]
|
|
|
|
|
|
L. van der Voort, A Kok, A Visser, C. Oudejans, M Caldano, F Gilli, A Bertolotto, C. Polman, and J Killestein Interferon-{beta} bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice Multiple Sclerosis, February 1, 2009; 15(2): 212 - 218. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Gilli, P. Valentino, M. Caldano, L. Granieri, M. Capobianco, S. Malucchi, A. Sala, F. Marnetto, and A. Bertolotto Expression and regulation of IFN{alpha}/{beta} receptor in IFN{beta}-treated patients with multiple sclerosis Neurology, December 9, 2008; 71(24): 1940 - 1947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Soelberg Sorensen Review: Neutralizing antibodies against interferon-beta Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 125 - 141. [Abstract] [PDF]
|
|
|
|
|
|
P. Sorensen, N Koch-Henriksen, E. Flachs, and K Bendtzen Is the treatment effect of IFN-{beta} restored after the disappearance of neutralizing antibodies? Multiple Sclerosis, July 1, 2008; 14(6): 837 - 842. [Abstract] [PDF]
|
|
|
|
|
|
C Gneiss, M Brugger, A Millonig, A Fogdell-Hahn, D Rudzki, J Hillert, T Berger, M Reindl, and F Deisenhammer Comparative study of four different assays for the detection of binding antibodies against interferon-{beta} Multiple Sclerosis, July 1, 2008; 14(6): 830 - 836. [Abstract] [PDF]
|
|
|
|
|
|
S. Malucchi, F. Gilli, M. Caldano, F. Marnetto, P. Valentino, L. Granieri, A. Sala, M. Capobianco, and A. Bertolotto Predictive markers for response to interferon therapy in patients with multiple sclerosis Neurology, March 25, 2008; 70(13_Part_2): 1119 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Sominanda, J Hillert, and A Fogdell-Hahn In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent J. Neurol. Neurosurg. Psychiatry, January 1, 2008; 79(1): 57 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Boz, J. Oger, E. Gibbs, S.E. Grossberg, and the Neurologists of the UBC MS Clinic Reduced effectiveness of long-term interferon-{beta} treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study Multiple Sclerosis, November 1, 2007; 13(9): 1127 - 1137. [Abstract] [PDF]
|
|
|
|
|
|
R. A Farrell and G. Giovannoni Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis Multiple Sclerosis, June 1, 2007; 13(5): 567 - 577. [Abstract] [PDF]
|
|
|
|
|
|
F. Deisenhammer Neutralizing antibody (NAb) assays in multiple sclerosis patients receiving interferon-{beta} therapy Multiple Sclerosis, May 1, 2007; 13(1_suppl): 44 - 48. [Abstract] [PDF]
|
|
|
|
|
|
F Gilli, F Hoffmann, A Sala, F Marnetto, M Caldano, P Valentino, L Kappos, A Bertolotto, and R L. Lindberg Qualitative and quantitative analysis of antibody response against IFN{beta} in patients with multiple sclerosis Multiple Sclerosis, November 1, 2006; 12(6): 738 - 746. [Abstract] [PDF]
|
|
|
|
|
|
F Gilli, F Marnetto, M Caldano, A Sala, S Malucchi, M Capobianco, and A Bertolotto Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1 Multiple Sclerosis, February 1, 2006; 12(1): 47 - 57. [Abstract] [PDF]
|
|
|
|
|
|
L. Kappos, M. Clanet, M. Sandberg-Wollheim, E. W. Radue, H. P. Hartung, R. Hohlfeld, J. Xu, D. Bennett, A. Sandrock, S. Goelz, et al. Neutralizing antibodies and efficacy of interferon {beta}-1a: A 4-year controlled study Neurology, July 12, 2005; 65(1): 40 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Francis, G. P.A. Rice, J. C. Alsop, and for the PRISMS (Prevention of Relapses and Disabil Interferon {beta}-1a in MS: Results following development of neutralizing antibodies in PRISMS Neurology, July 12, 2005; 65(1): 48 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Sorensen, N. Koch-Henriksen, C. Ross, K. M. Clemmesen, K. Bendtzen, and the Danish Multiple Sclerosis Study Group Appearance and disappearance of neutralizing antibodies during interferon-beta therapy Neurology, July 12, 2005; 65(1): 33 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Gneiss, M Reindl, A Lutterotti, R Ehling, R Egg, M Khalil, T Berger, and F Deisenhammer Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity Multiple Sclerosis, October 1, 2004; 10(5): 507 - 510. [Abstract] [PDF]
|
|
|
|
|
|
G Giovannoni Is it time to consider rationalising IFN-{beta} treatment in individuals with multiple sclerosis? J. Neurol. Neurosurg. Psychiatry, September 1, 2004; 75(9): 1234 - 1234. [Full Text] [PDF]
|
|
|
|
|
|
A Bertolotto, A Sala, S Malucchi, F Marnetto, M Caldano, A Di Sapio, M Capobianco, and F Gilli Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies J. Neurol. Neurosurg. Psychiatry, September 1, 2004; 75(9): 1294 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. P. Yeung, J. Chang, J. Miller, C. Barnett, M. Stickler, and F. A. Harding Elimination of an Immunodominant CD4+ T Cell Epitope in Human IFN-{beta} Does Not Result in an In Vivo Response Directed at the Subdominant Epitope J. Immunol., June 1, 2004; 172(11): 6658 - 6665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Gilli, A. Bertolotto, A. Sala, F. Hoffmann, M. Capobianco, S. Malucchi, T. Glass, L. Kappos, R. L.P. Lindberg, and D. Leppert Neutralizing antibodies against IFN-{beta} in multiple sclerosis: antagonization of IFN-{beta} mediated suppression of MMPs Brain, February 1, 2004; 127(2): 259 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Pachner An improved ELISA for screening for neutralizing anti-IFN-{beta} antibodies in MS patients Neurology, November 25, 2003; 61(10): 1444 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Pachner, J. Oger, and J. Palace The measurement of antibodies binding to IFN{beta} in MS patients treated with IFN{beta} Neurology, November 11, 2003; 61(90095): S18 - 20. [Full Text]
|
|
|
|
|
|
A. R. Pachner, A. Bertolotto, and F. Deisenhammer Measurement of MxA mRNA or protein as a biomarker of IFN{beta} bioactivity: Detection of antibody-mediated decreased bioactivity (ADB) Neurology, November 11, 2003; 61(90095): S24 - 26. [Abstract] [Full Text]
|
|
|
|
|
|
R. A. Rudick Biologic impact of interferon antibodies, and complexities in assessing their clinical significance Neurology, November 11, 2003; 61(90095): S31 - 34. [Abstract] [Full Text]
|
|
|
|
|
|
A. Bertolotto, F. Gilli, A. Sala, M. Capobianco, S. Malucchi, E. Milano, F. Melis, F. Marnetto, R. L.P. Lindberg, R. Bottero, et al. Persistent neutralizing antibodies abolish the interferon {beta} bioavailability in MS patients Neurology, February 25, 2003; 60(4): 634 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Kob, J Harvey, F Schautzer, S Kascha, D Bibl, R Egg, M Reindl, T Berger, and F Deisenhammer A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta Multiple Sclerosis, February 1, 2003; 9(1): 32 - 35. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Scagnolari, M. Casato, F. Bellomi, F. De Pisa, O. Turriziani, R. Coviello, M. R. Pirro, F. Dianzani, and G. Antonelli Serum Interferon (IFN)-Neutralizing Antibodies and Bioactivities of IFNs in Patients with Severe Type II Essential Mixed Cryoglobulinemia Clin. Vaccine Immunol., January 1, 2003; 10(1): 70 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Giovannoni, F E Munschauer 3rd, and F Deisenhammer Neutralising antibodies to interferon beta during the treatment of multiple sclerosis J. Neurol. Neurosurg. Psychiatry, November 1, 2002; 73(5): 465 - 469. [Full Text] [PDF]
|
|
|
|
|
|
A Bertolotto, S Malucchi, A Sala, G Orefice, P B Carrieri, M Capobianco, E Milano, F Melis, and M T Giordana Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory J. Neurol. Neurosurg. Psychiatry, August 1, 2002; 73(2): 148 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-M. Vallittu, M. Halminen, J. Peltoniemi, J. Ilonen, I. Julkunen, A. Salmi, J.-P. Eralinna, and the Finnish Beta-Interferon Study Group Neutralizing antibodies reduce MxA protein induction in interferon- beta-1a-treated MS patients Neurology, June 25, 2002; 58(12): 1786 - 1790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Cook, J. R. Quinless, A. Jotkowitz, and P. Beaton Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients Neurology, September 25, 2001; 57(6): 1080 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Pachner Measurement of Antibodies to Interferon Beta in Patients With Multiple Sclerosis Arch Neurol, August 1, 2001; 58(8): 1299 - 1300. [Full Text] [PDF]
|
|
|
|
|
|
Y. C. Q. Zang, D. Yang, J. Hong, M. V. Tejada-Simon, V. M. Rivera, and J. Z. Zhang Immunoregulation and blocking antibodies induced by interferon beta treatment in MS Neurology, August 8, 2000; 55(3): 397 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Deisenhammer, I. Mayringer, J. Harvey, E. Dilitz, T. Gasse, D. Stadlbauer, M. Reindl, and T. Berger A comparative study of the relative bioavailability of different interferon beta preparations Neurology, June 13, 2000; 54(11): 2055 - 2060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kracke, P. von Wussow, A. N. Al-Masri, G. Dalley, A. Windhagen, and F. Heidenreich Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS Neurology, January 11, 2000; 54(1): 193 - 193. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
